Belantamab Mafodotin with Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: A Comprehensive Exposure-Response Analysis of the DREAMM-8 Study.
Saved in:
| Title: | Belantamab Mafodotin with Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: A Comprehensive Exposure-Response Analysis of the DREAMM-8 Study. |
|---|---|
| Authors: | Hanafin P; GSK, 1250 S Collegeville Rd, Collegeville, PA, 19426, USA., Ho YL; GSK, 1250 S Collegeville Rd, Collegeville, PA, 19426, USA., Papathanasiou T; GSK, Baar, Switzerland., Fulci G; GSK, Waltham, MA, USA., Sule N; GSK, 1250 S Collegeville Rd, Collegeville, PA, 19426, USA., Kremer BE; GSK, 1250 S Collegeville Rd, Collegeville, PA, 19426, USA., Ferron-Brady G; GSK, 1250 S Collegeville Rd, Collegeville, PA, 19426, USA. geraldine.x.ferron@gsk.com. |
| Source: | Targeted oncology [Target Oncol] 2025 Sep; Vol. 20 (5), pp. 833-845. Date of Electronic Publication: 2025 Sep 16. |
| Publication Type: | Journal Article; Clinical Trial, Phase III; Multicenter Study; Randomized Controlled Trial |
| Journal Info: | Publisher: Springer-Verlag France Country of Publication: France NLM ID: 101270595 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1776-260X (Electronic) Linking ISSN: 17762596 NLM ISO Abbreviation: Target Oncol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
